Holocene Advisors
NBIX icon

Holocene Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Holocene Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,209
Closed -$731K – 842
2025
Q3 		$731K Buy
+5,209
New +$706K ﹤0.01% 654
2024
Q3 		– Sell
-185,344
Closed -$25.5M – 810
2024
Q2 		$25.5M Buy
+185,344
New +$25.4M 0.11% 195
2022
Q3 		– Sell
-692,611
Closed -$67.5M – 907
2022
Q2 		$67.5M Buy
+692,611
New +$63.9M 0.41% 80
2019
Q3 		– Sell
-175,620
Closed -$14.8M – 813
2019
Q2 		$14.8M Buy
+175,620
New +$14.4M 0.19% 125

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Holocene Advisors's NBIX Position: Q4 2025 in Review

Holocene Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 5,209 shares — an estimated $731K sold.

Holocene Advisors first reported a position in NBIX in Q2 2019 and held it in 4 quarters. The position peaked at $67.5M in Q2 2022. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Holocene Advisors reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Holocene Advisors sold 5,209 Neurocrine Biosciences shares in Q4 2025, an estimated $731K.
  • Holocene Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 4 quarters.
  • Holocene Advisors's Neurocrine Biosciences position peaked at $67.5M in Q2 2022.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Holocene Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.